You are here

New Insulin Delivery Device Launched in U.S.

Levemir FlexTouch contains insulin detemir

A new prefilled insulin delivery device, Levemir FlexTouch (insulin detemir [rDNA origin] injection), is now available in the U.S.

According to the product’s manufacturer (Novo Nordisk), when a dose is dialed with traditional prefilled insulin pens, the push button extends, and at larger doses this may present delivery challenges for the patient. Levemir FlexTouch is the first prefilled insulin delivery device with no push-button extension.

The prefilled pen contains 300 units of insulin detemir. The pen doses in one-unit increments, from one to 80 units, and is compatible with both NovoFine and the latest NovoTwist needles.

Levemir FlexTouch was approved by the FDA in November 2013. The device is available on more than 96% of commercial and Medicare Part D plans nationwide, including exclusive tier 1 status on UnitedHealthcare and preferred status on Coventry.

Source: Novo Nordisk; June 19, 2014.

Recent Headlines

Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
May Lead to Personalized Treatment for Schizophrenia, Other Illnesses
Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
First Medicines for Adults With Wild-type or Hereditary ATTR-CM